Business
MedX Health 2025 YEAR REVIEW
MedX Health Corp. (TSXV: MDX) (“ MedX ” or the “ Company ”)...
About this update from Medx Health Corp.
[{"type":"text","content":"MedX Health 2025 YEAR REVIEW\n\n\n .bwlistdisc { list-style-type: disc }\n \n\n\n\n\n MedX Health Corp.\n \n (TSXV: MDX) (“\n \n MedX\n \n ” or the “\n \n Company\n \n ”) is a\n \n data-driven health analytics business\n \n underpinned by proprietary intellectual property and regulated medical technologies. MedX’s platform generates and analyses high-fidelity skin health data using patented imaging, Teledermatology, and Photobiomodulation systems, creating a growing, defensible data asset and IP moat. MedX operates as an ISO 13485–certified medical device manufacturer and maintains compliance across FDA, Health Canada, MDSAP, CE, HIPAA, and GDPR frameworks.\n \n\n As we close 2025, the Company is pleased to provide shareholders with a year-in-review operational update highlighting its progress, execution, and strategic direction.\n \n\n\n 2025 Operational and Strategic Update\n \n\n\n During fiscal 2025, MedX invested over CAD$2 million in the continued development of its technology platform, intellectual property portfolio, compliance and operational infrastructure. These investments included targeted hires across executive leadership, technology, and operations, and were focused on strengthening the Company’s long-term commercial readiness and IP position in preparation for large scale roll-out in 2026.\n \n\n\n DermSecure® and SIAscopy\n \n ®\n \n\n MedX continued to strengthen its DermSecure® Platform by expanding and improving its proprietary image database, which now includes approximately 85,000 clinically reviewed skin images. Each image contains detailed information about key skin components such as blood, melanin and collagen (structural tissue), which allows clinicians to see beneath the surface of the skin so that they may make accurate assessments. This growing data set is a core asset of the Company, supporting the development and testing of MedX’s software, protecting its intellectual property, and enabling the use of artificial intelligence to improve skin analysis and clinical decision-making.\n \n\n In Q3 2025, MedX appointed a new Chief Executive Officer and its first Chief Technology Officer, consolidating responsibility for technology development across two specialist teams. The CTO works with internal engineers and external advisers in d...